From left, Sage Therapeutics Amy Schacterle, Al Robichaud, chief executive Jeff Jonas, Chris Silber, and Frank Salituro posed for a portrait at their Cambridge office.
Earlier in his career, Paul Bolno worked with neuroscientists at drug giant GlaxoSmithKline PLC. Today, as chief executive of Wave Life Sciences Ltd., he is leading the Cambridge biotechs effort to advance two experimental drugs that could become the first treatments for the progressive brain disorder Huntingtons disease.
Bolnos move from Big Pharma to biotech reflects a broader transition at businesses working on medicines for neurological diseases. As more than 10,000 doctors and scientists converge on Boston this week for the annual convention of the American Academy of Neurology, much of the fields progress is being made inside smaller entrepreneurial companies.
Advertisement
The biotechs are moving the science forward, said Bolno, whose company last week closed on a $150 million financing round and will open a Lexington plant this summer to make drugs for clinical trials. There was a mass exodus of pharma companies from the neurological space, and that created an opportunity for companies like ours. The large companies are now on the sidelines trying to get back in.
With new neurodegenerative treatments finally emerging after more than a decade during which there wasnt much innovation going on, a cluster of local biotechs including Wave, Sarepta Therapeutics Inc., Sage Therapeutics Inc., Voyager Therapeutics Inc., and Yumanity Therapeutics Inc. is attracting investment money, making the Boston area a growing hub for drug development in the field. They are working on some of the most intractable diseases of the brain and nervous system, including Alzheimers, Parkinsons, and Huntingtons.
Get Talking Points in your inbox:
An afternoon recap of the days most important business news, delivered weekdays.
Neurology is the new oncology, said Alfred Sandrock, chief medical officer at Biogen Inc. of Cambridge, referring to the cancer research field that has long commanded the biopharma spotlight. People are getting interested in neurology as the next frontier.
Sage chief executive Jeff Jonas, whose company has a drug being tested in late-stage trials to treat postpartum depression and a type of epilepsy, said some in the industry initially asked him whether a small biotech could tackle central nervous system disorders.
I fundamentally believe that biotechs are ideally situated to do this kind of innovation, said Jonas, who noted that five-year-old Sage has grown from 14 to about 180 employees attracted by its work on multiple drug candidates. Following Big Pharma has not been a recipe for success.
Advertisement
Biogen, one of the larger players in the burgeoning field, has built the worlds leading portfolio of multiple sclerosis medicines. Late last year, it won US approval for Spinraza, the first drug to treat spinal muscular atrophy. Three months earlier, Sarepta got the nod from the Food and Drug Administration for Exondys 51, the first treatment for Duchenne muscular dystrophy.
Companies now see a path for [drug] approval, so theres a lot of investment in the field, Sarepta chief executive Edward Kaye said. His company will make presentations on its drug at the Boston neurology meeting.
But focusing on brain, nervous system, and muscular disorders remains a risky business with a high rate of attrition. While some diseases have been linked to specific genetic mutations, scientists are still puzzling over the underlying causes of others. Hundreds of research programs aimed at developing treatments for Alzheimers disease, considered a holy grail in the neurology field, have failed over the last several decades.
In clinical data reported last year, Biogens experimental compound abucanumab appeared to slow progression of the memory-wasting neurodegenerative disorder, which afflicts an estimated 47 million people worldwide. Earlier this month, Biogen licensed another experimental drug from Bristol-Myers Squibb Co. that fights Alzheimers in a different way. Other companies, including some in Massachusetts, are also working on Alzheimers treatments.
We see light at the end of the tunnel, said Martin Tolar, chief executive of Alzheon Inc., a Framingham biotech that wants to develop a pill that could prevent toxic proteins known as oligomers from forming clumps in the brain. Alzheimers research is getting to the point where we will start to see treatments some time in the next few years.
Excitement has been building in the neuroscience field, said Michelle Hoffmann, senior vice president at Back Bay Life Science Advisors in Boston. These are diseases with extremely high unmet medical need, she said. Youre seeing a better understanding of the biological basis of these diseases, and people are chipping away. The large companies werent able to crack it open, but the smaller companies and venture funds [backing them] are keeping the flame alive.
The recent progress raises hope that new therapies can emerge for other devastating neurological diseases like Parkinsons, and amyotrophic lateral sclerosis, known as Lou Gehrigs disease, which currently have no treatments. But over the past five years, big players like GlaxoSmithKline, Pfizer Inc., Novartis AG, and AstraZeneca PLC, stung by setbacks and long development cycles, have scaled back their research into brain disorders. While they have shut down or jettisoned many programs, they continue to monitor the biotechs, standing ready to form partnerships on promising research.
At this weeks neurology gathering at the Boston Convention and Exhibition Center, professionals in the field will discuss everything from deploying monoclonal antibody therapies for migraine prevention to using medical marijuana to treat epileptic seizures. Among the scientific approaches that will be highlighted in clinical data presentations will be exon skipping, a way to program cells to skip over disease-causing genetic code, and therapies that can correct defective genes involved in neuromuscular disorders.
We are gaining momentum in a new generation of gene therapies that are safer and more targeted, said Dr. Natalia Rost, a stroke neurologist at Massachusetts General Hospital and incoming chairwoman of the neurology academys science committee.
She cited an experimental gene therapy treatment developed by Cambridge-based Bluebird Bio to treat cerebral adrenoleukodystrophy, a potentially fatal nerve disease, and another by AveXis Inc. of Bannockburn, Ill., to treat the most severe form of spinal muscular atrophy.
Many of these experimental drugs are still years away from widespread use. But for scientists long starving for progress, the innovative approaches are reason for optimism.
The brain is an extremely complex organ, and its constantly changing, Hoffmann said. So to understand what goes wrong, its an order of complexity greater than other organs.
Originally posted here:
Biotechs take lead in a new push against neurological disorders - The Boston Globe
- Muscular .Dystrophy -Successful-treatment by acupressure , Ayurveda, Yoga - May 10th, 2011 [May 10th, 2011]
- Muscular Dystrophy Treatment - Todd Harrison Improving Balance - May 16th, 2011 [May 16th, 2011]
- Oculopharyngeal Muscular Dystrophy (OPMD): Exploring Causes and Treatment - May 20th, 2011 [May 20th, 2011]
- Muscular Dystrophy Treatment - Todd Harrison holding body weight - May 21st, 2011 [May 21st, 2011]
- David G VECTTOR Muscular Dystrophy Treatment double arm strength month 6 - May 22nd, 2011 [May 22nd, 2011]
- David Gould Becker Muscular Dystrophy VECTTOR Treatment - June 2nd, 2011 [June 2nd, 2011]
- Muscular Dystrophy Halo - June 3rd, 2011 [June 3rd, 2011]
- Muscular Dystrophy VECTTOR Treatment Documentary - Todd's 6 Month Journey - June 7th, 2011 [June 7th, 2011]
- Muscular Dystrophy Treatment Results - David Gould - New Footage - June 8th, 2011 [June 8th, 2011]
- Muscular Dystrophy - Rewriting History with VECTTOR - June 10th, 2011 [June 10th, 2011]
- Muscular Dystrophy - David Gould 5 month VECTTOR treatment for BMD - June 12th, 2011 [June 12th, 2011]
- Duchenne's Muscular Dystrophy Stem Cell Treatment - Reelabs India - June 14th, 2011 [June 14th, 2011]
- Muscular Dystrophy VECTTOR Treatment - Todd Harrison/Luau Presentation - June 16th, 2011 [June 16th, 2011]
- Dr. William Rader - Muscular Dystrophy Breakthrough - June 16th, 2011 [June 16th, 2011]
- Muscular Dystrophy patient at Xcell-center - Nabeel Mohamed Abdulhusain, 46 years - June 17th, 2011 [June 17th, 2011]
- Charlie's Story: Duchenne Muscular Dystrophy Part 4 - July 18th, 2011 [July 18th, 2011]
- Muscular Dystrophy VECTTOR Treatment - David Gould/Luau Presentation - July 19th, 2011 [July 19th, 2011]
- Testimonial 4 of Muscular Dystrophy after Stem Cell Therapy - August 5th, 2011 [August 5th, 2011]
- Drug Combo Dynamic in Muscular Dystrophy - August 9th, 2011 [August 9th, 2011]
- Testimonial for Fetal Stem Cell Treatment of Duchenne Muscular Dystrophy - August 25th, 2011 [August 25th, 2011]
- Improvement seen in Duchenne Muscular Dystrophy after Stem Cell Therapy - September 11th, 2011 [September 11th, 2011]
- Muscular Dystrophy STS/VECTTOR treatment results - September 24th, 2011 [September 24th, 2011]
- Muscular Dystrophy VECTTOR Treatment Documentary - Todd's One Year Journey - October 2nd, 2011 [October 2nd, 2011]
- Muscular Dystrophy Treatment Day 18 - Todd Harrison's Improvement - October 2nd, 2011 [October 2nd, 2011]
- Wang Yisheng - Muscular Dystrophy Adult Stem Cell Patient - October 9th, 2011 [October 9th, 2011]
- Becker Muscular Dystrophy Miracle TREATMENT - October 11th, 2011 [October 11th, 2011]
- Muscular dystrophy patient_Kleber_Brazil.wmv - October 12th, 2011 [October 12th, 2011]
- Testimonial 1 of Muscular Dystrophy after Stem Cell Therapy - Video - October 18th, 2011 [October 18th, 2011]
- Becker Muscular Dystrophy STS Treatment - Video - October 18th, 2011 [October 18th, 2011]
- Potential Stem Cell treatment of Duchenne Muscular Dystrophy - Video - October 21st, 2011 [October 21st, 2011]
- Muscular Dystrophy treated by Dr Rajesh Shah at Life Force - Video - October 22nd, 2011 [October 22nd, 2011]
- Defying Muscular Dystrophy - I Made It - Video - October 23rd, 2011 [October 23rd, 2011]
- Becker Muscular Dystrophy AMAZING treatment results - Video - October 27th, 2011 [October 27th, 2011]
- First targeted treatment success for Duchenne muscular dystrophy - Video - November 6th, 2011 [November 6th, 2011]
- 125 Days of VECTTOR Treatment Progress - November 18th, 2011 [November 18th, 2011]
- Becker Muscular Dystrophy WALKING ABILITY IMPROVED - Video - November 25th, 2011 [November 25th, 2011]
- PT Muscular Dystrophy Treatment Results - Video - December 5th, 2011 [December 5th, 2011]
- Duchenne Muscular Dystrophy Treated by Cellmedicine - Video - January 8th, 2012 [January 8th, 2012]
- muscular DYSTROPHY treatment IN HOMEOPATH.mp4 - Video - January 28th, 2012 [January 28th, 2012]
- Giulio's strategy is to cure dystrophy with stem cell treatment - Video - January 31st, 2012 [January 31st, 2012]
- Parent Project Muscular Dystrophy is a Featured Nonprofit Selected by Webkinz(TM) Foundation - February 1st, 2012 [February 1st, 2012]
- MDA Awards More Than $12 Million in Grants to Advance Neuromuscular Disease Research - February 1st, 2012 [February 1st, 2012]
- "For treatment we will have in the future" - Video - February 2nd, 2012 [February 2nd, 2012]
- Renowned Pediatric Cardiology Physician-Scientist Linda Cripe Joins Nationwide Children's Hospital - February 3rd, 2012 [February 3rd, 2012]
- JumpStart Invests $250,000 in Milo Biotechnology - February 14th, 2012 [February 14th, 2012]
- When nerve meets muscle, biglycan seals the deal - February 14th, 2012 [February 14th, 2012]
- Medical clinics offer help for Big Island children - February 16th, 2012 [February 16th, 2012]
- Dateline Long Beach: The Aquatic Center brings swim therapy to disabled - February 19th, 2012 [February 19th, 2012]
- Parent Project Muscular Dystrophy Awards $500,000 to Tivorsan Pharmaceuticals - February 21st, 2012 [February 21st, 2012]
- Cure Duchenne Announces Three New Funded Research Projects to Help Develop Treatments and Find a Cure for Duchenne ... - February 21st, 2012 [February 21st, 2012]
- Ligand Licenses DARA Program to Retrophin - February 21st, 2012 [February 21st, 2012]
- AVI BioPharma Regains NASDAQ Compliance - February 23rd, 2012 [February 23rd, 2012]
- Scientists create potent molecules aimed at treating muscular dystrophy - February 23rd, 2012 [February 23rd, 2012]
- AVI BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results and Corporate Update Conference Call - February 23rd, 2012 [February 23rd, 2012]
- Pembroke's Christine McSherry is an 'Inspirational Woman' - February 25th, 2012 [February 25th, 2012]
- The Rare Clinical Diseases Research Network - February 25th, 2012 [February 25th, 2012]
- A Solution for Duchenne Muscular Dystrophy? - Research Summary - February 28th, 2012 [February 28th, 2012]
- A Solution for Duchenne Muscular Dystrophy? -- In Depth Doctor's Interview - February 28th, 2012 [February 28th, 2012]
- Antisense oligonucleotides make sense in myotonic dystrophy - February 28th, 2012 [February 28th, 2012]
- A life of dependence - February 29th, 2012 [February 29th, 2012]
- Nationwide Children's Hospital neuromuscular disorder podcasts now available on iTunes - March 2nd, 2012 [March 2nd, 2012]
- Next-generation DNA sequencing to improve diagnosis for muscular dystrophy - March 6th, 2012 [March 6th, 2012]
- The Dire Limits of Health Care - March 7th, 2012 [March 7th, 2012]
- AVI BioPharma Announces Late-Breaker Oral Presentation of Phase IIb DMD Study at 2012 AAN Annual Meeting in April - March 12th, 2012 [March 12th, 2012]
- Cataracts affect millions of people around the globe, and for many of us they will be a normal part of our aging ... - March 14th, 2012 [March 14th, 2012]
- Your Health: Duchenne's Muscular Dystrophy - March 16th, 2012 [March 16th, 2012]
- Newborn Screening for Duchenne Muscular Dystrophy Shows Promise as an International Model - March 20th, 2012 [March 20th, 2012]
- Newborn screening for DMD shows promise as an international model - March 20th, 2012 [March 20th, 2012]
- Rhenovia launches drug discovery for Huntington's disease - March 20th, 2012 [March 20th, 2012]
- Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100 - March 21st, 2012 [March 21st, 2012]
- Invasive treatment strategy may increase survival for patients with certain neuromuscular disorder - March 28th, 2012 [March 28th, 2012]
- Parent Project Muscular Dystrophy Endorses FAST Act Legislation to Expedite FDA Review of Life-Saving Therapies - March 29th, 2012 [March 29th, 2012]
- AVI BioPharma Announces Conference Call and Webcast on Monday, April 2, 2012, to Discuss Top-Line Data Results From ... - March 31st, 2012 [March 31st, 2012]
- Drug for rare disease may lift AVI BioPharma shares: Barron's - April 2nd, 2012 [April 2nd, 2012]
- AVI BioPharma Announces Eteplirsen Meets Primary Endpoint, Demonstrating a Significant Increase in Dystrophin at 24 ... - April 2nd, 2012 [April 2nd, 2012]
- U.S. Stock Futures Little Changed Before Factory Report - April 2nd, 2012 [April 2nd, 2012]
- Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno - April 20th, 2012 [April 20th, 2012]
- Nature Publishes Work Utilizing N-Gene's Core Technology to Advance the Treatment of Duchenne Muscular Dystrophy - April 20th, 2012 [April 20th, 2012]
- Getting the boots filled - April 29th, 2012 [April 29th, 2012]
- Local business, civic leaders 'arrested' for MDA fundraiser - May 3rd, 2012 [May 3rd, 2012]